Novel Drug Delivery Systems in the management of CNS Disorders

Dr. Pooja A Chawla is a Professor, Department of Pharmaceutical Chemistry, ISF College Of Pharmacy Moga, India. She Has 19 Years of Experience in the Research, Discovery And Development Of Biologically Active Pharmaceuticals. Dr. Chawla Holds a Ph D Degree In Medicinal Chemistry and Has Published 3 Books, 5 Book Chapters and More Than 60 Papers In National/International Journals and Is serving as reviewer for international journals of repute. Dr. Chawla Is also Privileged to serve as guest editor of two reputed journals of Bentham Sciences. She has guided 47 Post Graduate Projects And Her Research Team Consists Of 3 Master And 4 Doctoral Research Scholars. Her area of research Interest focuses on the design And synthesis of various heterocyclic moieties. Dr. Löbenberg holds a BSc in pharmacy from the Johannes Gutenberg-University in Mainz, Germany. He received his PhD in pharmaceutics from the Johann Wolfgang Goethe-University in Frankfurt in 1996. He joined the University of Alberta in 2000. His research interests are in Biopharmaceutics to predict the oral performance of drugs and botanicals and inhalable nanoparticles to treat lung diseases like cancer or tuberculosis. He is founder and director of the Drug Development and Innovation Centre at the University of Alberta. He was president of the Canadian Society for Pharmaceutical Sciences 2014 & 2015. He is member of the United States Pharmacopeia Dietary Supplement Expert Committee. He is Vice Chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science. He is member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology. Dr Kamal Dua is an award-winning pharmaceutics and drug delivery researcher who has deep roots in teaching, research and industry spanning three nations and two continents. He holds dual expertise in Pharmaceutical Sciences and Immunology & Microbiology and has also completed four professional diplomas in the areas of clinical research, product development, drug regulation, and documentation and intellectual property rights. In his role as a senior lecturer in the Graduate School of Health at UTS, Kamal leads a suite of Good Manufacturing Practice (GMP) courses where, as a Program Coordinator, his responsibilities include coordinating the academic and research activities for those courses. Drawing on his experience with various pharmacy schools in Australia and overseas, he has blended different modes of innovative teaching with traditional teaching modes to create a flexible, student-centred and engaging approach to pedagogy. Dr Vinay Parikh, is an Associate Professor in the Cognition and Neuroscience area of the Department of Psychology at Temple University. Dr. Parikh also holds an affiliated faculty appointment in the Center for Substance Abuse Research at Lewis Katz School of Medicine. Previously, he served as the Director of Neuroscience Program in the College of Liberal Arts and provided strategic leadership, direction, and guidance for all educational and professional activities in the program. Dr. Parikh’s research interests broadly focus on neuromodulation of cognition in health and disease. For many years, his laboratory is engaged in delineating the contributions of cholinergic and glutamatergic signaling in modulation of distinct cognitive processes, specifically those involved in attention and executive functions. His research has also focused on the role of neurotrophins as key regulators of neurochemical circuit adaptations and cognitive functioning in aging and psychiatric disorders such as drug addiction and schizophrenia. Dr. Viney Chawla is working as Professor and Principal at University Institute of Pharmaceutical Sciences and Research, Baba Farid University of Health Sciences, Punjab, India, He has 23 years of experience In the research, formulation and development of solid lipid nanoparticles, microspheres, nanostructured lipid carriers. Dr. Chawla Holds a Ph. D Degree In Pharmaceutics And Has Published 1 Book, 21 Book Chapters And More Than 60 Papers In National/International Journals And Is Serving as A Reviewer For International Journals Of Repute. Dr. Chawla delivered An Oral Talk at World Chemistry Congress, Dubai 2019. He Has Guided 40 Post Graduate Projects And his Research Team Consists Of 4 Master And 3 Doctoral Research Scholars.

Part I Introduction to Drug delivery to the CNS
1. General physiology and function of brain
2. Formulator’s challenges for delivering drugs to the brain
3. Possible targets in the management of various CNS disorders
4. Antioxidants and their possible benefits in neurodegeneration
5. Prodrug approaches for delivering CNS active agents
6. Traditional practices in CNS drug delivery
7. Emerging need of Novel Drug Delivery Systems in management of CNS disorders
8. Nose to brain drug delivery through advanced Drug Delivery Systems
9. PBPK modeling for CNS Delivery

Part II Novel Drug Delivery Systems to specific CNS Disorders
10: Novel Drug Delivery Systems in treating epilepsy
11. Novel Drug Delivery Systems in the management of Parkinson’s Disease
12. Role of Novel Drug Delivery Systems in managing Alzheimer’s Disease
13. Novel Drug Delivery Systems in the management of Huntington’s Disease
14. Novel Drug Delivery Systems in the management of multiple sclerosis
15. Role of Novel Drug Delivery Systems in delivering antidepressant drugs to the brain
16. Delivering cancer chemotherapeutics to the brain through Novel Drug Delivery Systems
17. Novel Drug Delivery Systems in the management of Schizophrenia
18. Prospects of Novel Drug Delivery Systems in treating cerebral palsy
19. Targeting phytoconstituents to the brain through Novel Drug Delivery Systems
20. Novel Drug Delivery Systems in managing autism
21. Novel Drug Delivery Systems in amyotrophic lateral sclerosis
22. Novel Drug Delivery Systems in cerebral vascular disorders, transient ischemic attack and stroke interventions
23. Treating meningitis through Novel Drug Delivery Systems
24. Treatment of CNS infections in AIDS positive patients through Novel Drug Delivery Systems
25. Novel Drug Delivery Systems in the management of myasthenia gravis
26. Managing Concussions and traumatic brain injury through NDDS
27. Trends in delivery of drugs to brain for treatment of neuropathy
28. Delivery of antimigraine drugs to brain through Novel Drug Delivery Systems
29. Treatment of heavy metal induced neurotoxicity via advanced drug delivery systems

Part III Clinical Trials and Future Prospects
30. Exploring the potential of artificial intelligence in drug delivery to brain
31. Clinical trials in drug discovery for treatment of CNS disorders
32. Future prospects and Challenges to CNS drug delivery